- Augurex to attend BIO 2025, June 16–19, in Boston, MA, the world’s largest biotechnology partnering event.
- Showcasing biomarker-based diagnostics for rheumatoid arthritis and axial spondyloarthritis, including JOINTstat® and first-in-class SPINEstat™.
Vancouver, Canada – June 6, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced its participation in the BIO International Convention 2025, taking place June 16–19 in Boston, MA.
As the world’s largest biotechnology partnering event, BIO brings together more than 15,000 industry leaders from over 65 countries to advance collaboration across biotech, pharma, and diagnostics.
At BIO 2025, we’ll highlight our work in biomarker-driven autoimmune diagnostics, including:
- JOINTstat® | 14-3-3eta: A blood-based biomarker test that supports the diagnosis and monitoring of rheumatoid arthritis (RA).
- SPINEstat™ | Anti-14-3-3eta Multiplex: A first-in-class diagnostic blood test for the early and accurate diagnosis of axial spondyloarthritis (axSpA), helping clinicians distinguish inflammatory disease from mechanical back pain.
These tools support earlier and more objective diagnosis and management of autoimmune diseases, helping clinicians reduce diagnostic delays, inform treatment decisions, and personalize care to improve outcomes.
Augurex continues to engage with partners and collaborators who share its vision for advancing precision diagnostics and expanding access to innovative tools that improve patient outcomes in RA and axSpA.
We welcome the opportunity to connect with industry leaders at BIO 2025. To explore partnership opportunities, reach out to Neil Klompas to connect during the event.
For more details about the event, visit:
BIO International Convention 2025
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein, is available as JOINTstat® in Canada and Great Britain, and is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs, available as SPINEstat™ in Canada and Great Britain, expands Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Media Contact
Nima Mazinani
(604) 674-8231
media@augurex.com